Compugen Ltd. (CGEN) is a Healthcare stock trading at $2.00 (as of 2026-06-18), with a market capitalization of $248.67M and a trailing P/E of 5.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Compugen Ltd. researches, develops, and commercializes antibody-based therapeutics, including immuno-oncology candidates such as COM701, COM902, Bapotulimab, and AZD2936. The company operates research activities in Israel and conducts development and related activities in the United States and Europe, including collaborations with partners such as Bayer Pharma AG.